“That’s very early,” Anna Durbin, a vaccine researcher at Johns Hopkins University, told STAT. “We don’t know if those antibodies are durable.”
The Moderna press release also indicated that the antibody levels observed were equal to or greater in the 100 ug dose than was seen in patients who recovered from COVID-19. There’s not much context here, because studies on recovered COVID-19 patients have shown a range that is potentially influenced by the severity of the disease. For example, John “Jack” Rose, a Yale University vaccine researcher told STAT about a study in China demonstrating that in 175 recovered COVID-19 patients, 10 had no detectable neutralizing antibodies, while others had very high antibody levels.
Of the Phase III trial, Fauci indicated that the majority of trial participants will be between the ages of 18 and 55, but will include elderly Americans that are most at risk of serious illness from COVID-19.
Comments are closed.